CN109414485B - 用于抑制脂多糖和脂质a的髓过氧化物酶组合物和方法 - Google Patents

用于抑制脂多糖和脂质a的髓过氧化物酶组合物和方法 Download PDF

Info

Publication number
CN109414485B
CN109414485B CN201780032711.9A CN201780032711A CN109414485B CN 109414485 B CN109414485 B CN 109414485B CN 201780032711 A CN201780032711 A CN 201780032711A CN 109414485 B CN109414485 B CN 109414485B
Authority
CN
China
Prior art keywords
myeloperoxidase
endotoxin
lipid
lipopolysaccharide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780032711.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109414485A (zh
Inventor
R·C·爱伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exoxemis Inc
Original Assignee
Exoxemis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exoxemis Inc filed Critical Exoxemis Inc
Publication of CN109414485A publication Critical patent/CN109414485A/zh
Application granted granted Critical
Publication of CN109414485B publication Critical patent/CN109414485B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780032711.9A 2016-05-27 2017-04-13 用于抑制脂多糖和脂质a的髓过氧化物酶组合物和方法 Active CN109414485B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342382P 2016-05-27 2016-05-27
US62/342,382 2016-05-27
PCT/US2017/027458 WO2017204918A1 (en) 2016-05-27 2017-04-13 Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a

Publications (2)

Publication Number Publication Date
CN109414485A CN109414485A (zh) 2019-03-01
CN109414485B true CN109414485B (zh) 2022-08-12

Family

ID=60411564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780032711.9A Active CN109414485B (zh) 2016-05-27 2017-04-13 用于抑制脂多糖和脂质a的髓过氧化物酶组合物和方法

Country Status (9)

Country Link
US (1) US11389514B2 (https=)
EP (1) EP3463431B1 (https=)
JP (3) JP6713546B2 (https=)
CN (1) CN109414485B (https=)
AU (1) AU2017269582B2 (https=)
CA (1) CA3022426C (https=)
IL (1) IL262930B2 (https=)
MX (1) MX392701B (https=)
WO (1) WO2017204918A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021000373A (es) * 2018-07-13 2021-04-12 Robert C Allen Composiciones de haloperoxidasa y usos de las mismas.
WO2022103565A1 (en) * 2020-11-13 2022-05-19 Exoxemis, Inc. Myeloperoxidase-containing compositions and uses thereof
JP2026500309A (ja) * 2022-12-14 2026-01-06 ユニヴェルシテ・ドゥ・ボルドー ミエロペルオキシダーゼ活性及びグルコースオキシダーゼ活性を含む人工二機能性酵素及びその適用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2108387B (en) 1979-12-28 1984-03-21 Green Cross Corp A pharmaceutical composition containing myeloperoxidase
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5622848A (en) * 1990-05-23 1997-04-22 Medical Discoveries, Inc. Electrically hydrolyzed salines as microbiocides for in vitro treatment of contaminated fluids containing blood
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
AU663869B2 (en) * 1991-02-21 1995-10-26 Exoxemis, Inc. Methods and compositions for the treatment of infection and control of flora
US5565197A (en) * 1991-02-21 1996-10-15 Exoxemis, Inc. Method which utilizes a haloperoxidase composition to inhibit the growth of microorganisms which cause sexually transmitted diseases
US5888505A (en) * 1991-02-21 1999-03-30 Eoe, Inc. Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system
US8945540B2 (en) * 2008-05-09 2015-02-03 Exoxemis, Inc. Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
AU2012281172B2 (en) * 2011-07-11 2016-11-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use

Also Published As

Publication number Publication date
EP3463431A4 (en) 2020-01-15
MX2018013925A (es) 2019-03-28
JP2019515881A (ja) 2019-06-13
MX392701B (es) 2025-03-24
JP2021181500A (ja) 2021-11-25
US11389514B2 (en) 2022-07-19
US20190183983A1 (en) 2019-06-20
EP3463431C0 (en) 2024-09-18
AU2017269582A1 (en) 2018-10-04
IL262930B2 (en) 2023-11-01
CA3022426C (en) 2023-05-16
AU2017269582B2 (en) 2023-12-21
EP3463431B1 (en) 2024-09-18
WO2017204918A1 (en) 2017-11-30
JP2020111620A (ja) 2020-07-27
CN109414485A (zh) 2019-03-01
IL262930A (en) 2018-12-31
CA3022426A1 (en) 2017-11-30
EP3463431A1 (en) 2019-04-10
IL262930B1 (en) 2023-07-01
JP6713546B2 (ja) 2020-06-24

Similar Documents

Publication Publication Date Title
RU2529799C2 (ru) Композиции для усиления антибактериальной активности миелопероксидазы и способы их применения
RU2654596C2 (ru) Композиции коктейля, содержащие антибактериальные фаги, и способы их применения
Tseng et al. Effects of toluidine blue O (TBO)-photodynamic inactivation on community-associated methicillin-resistant Staphylococcus aureus isolates
JP2021181500A (ja) リポ多糖およびリピドａの阻害のためのミエロペルオキシダーゼ組成物および方法
Lang et al. Tyrothricin–an underrated agent for the treatment of bacterial skin infections and superficial wounds?
CN103764137A (zh) 嗜伊红粒细胞过氧化物酶组合物和它们的使用方法
HK40005977A (en) Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a
HK40005977B (en) Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a
Ansorg et al. Influence of Mucin on the Activity of the Antiseptic Lavasept® against Staphylococcus aureus
Schneider et al. Biofilm Dispersal and Wound Infection Clearance With Preclinical Debridement Agents
Sadick et al. The intrinsic antimicrobial activity of selected sclerosing agents in sclerotherapy
EP4470525B1 (en) New stable gel formulations for the treatment of acne vulgaris
JP5140426B2 (ja) 齲蝕原因菌に選択的な殺菌剤、齲蝕原因菌を殺菌する方法
WO2023215850A3 (en) Compositions and methods for the treatment of actinomycetia infections
BRPI0909447B1 (pt) Composição para inibir o crescimento de microrganismos grampositivos e gram-negativos e uso de uma composição

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant